1.20
0.01 (0.84%)
0.01 (0.84%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 1,102,740 |
|
|||||
News | - | ||||||
Day High | 1.22 | Low High |
|||||
Day Low | 1.08 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Citius Pharmaceuticals Inc | CTXR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.13 | 1.08 | 1.22 | 1.17 | 1.19 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,266 | 1,102,740 | $ 1.17 | $ 1,290,750 | - | 0.8306 - 2.35 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:13:08 | 18 | $ 1.20 | USD |
Citius Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 175.36M | 146.13M | 133.82M | $ - | $ - | -0.27 | -5.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 8.40% |
Citius Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTXR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.9953 | 1.22 | 0.933 | 1.08 | 1,048,713 | 0.2047 | 20.57% |
1 Month | 0.91 | 1.22 | 0.8601 | 0.9834853 | 752,238 | 0.29 | 31.87% |
3 Months | 0.8976 | 1.22 | 0.8306 | 0.95742 | 1,151,721 | 0.3024 | 33.69% |
6 Months | 1.51 | 2.01 | 0.8306 | 1.24 | 1,539,514 | -0.31 | -20.53% |
1 Year | 1.83 | 2.35 | 0.8306 | 1.60 | 1,790,135 | -0.63 | -34.43% |
3 Years | 1.17 | 4.56 | 0.40 | 1.96 | 3,391,132 | 0.03 | 2.56% |
5 Years | 2.91 | 5.49 | 0.40 | 1.96 | 2,091,339 | -1.71 | -58.76% |
Citius Pharmaceuticals Description
Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |